📈 Neoadjuvant T-DXd followed by THP elicited faster and deeper tumor responses on MRI than ddAC-THP in HER2+ early breast cancer, but MRI response did not reliably predict pCR in a

OncLive.com· @OncLive · X·2026-10-24 22:12· 15 小时前评分70

正文 · 原文

📈 Neoadjuvant T-DXd followed by THP elicited faster and deeper tumor responses on MRI than ddAC-THP in HER2+ early breast cancer, but MRI response did not reliably predict pCR in a DESTINY-Breast11 analysis. @myESMO #ESMO2026 #bcsm #oncology

Read more: https://www.onclive.com/view/t-dxd-followed-by-thp-elicits-deep-mri-responses-in-her2-early-breast-cancer

171 浏览 · 1 赞 · 2 转发 · 0 回复

会议摘要

543RO按 Rapid oral: Breast cancer, early stage 对上

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (

https://esmocongress.esmo.org

来源：OncLive.com · x.com